Isosceles Pharmaceuticals

Isosceles Pharmaceuticals

Early Stage

Helping Solve America's Opioid Crisis

Helping Solve America's Opioid Crisis

Overview

Raised to Date: Raised: $5,000,000

Total Commitments ($USD)

Platform

Equifund CFP

Start Date

10/04/2022

Close Date

04/30/2023

Min. Goal
$20,000
Max. Goal
$5,000,000
Min. Investment

$500

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.05

Pre-Money Valuation

$30,800,000

Rolling Commitments ($USD)

Status
Funded
Reporting Date

05/02/2023

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$24,038

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2019

Industry

Healthcare & Pharmaceuticals

Tech Sector

Medtech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Wilmington, North Carolina

Business Type

Growth

Isosceles Pharmaceuticals, with a valuation of $30.8 million, is raising funds on Equifund CFP. It is a pharmaceutical company currently developing intravenous formulations of synthetic Cannabidiol as non-addictive alternatives to opium-based painkillers. The CBD formulations will be used for acute post-operative pain and will address the surgical population in the US, Europe, and the UK. Isosceles Pharmaceuticals is currently in the pre-clinical trials stage. Brett Lanier founded Isosceles Pharmaceuticals in April 2019. The current crowdfunding campaign has a minimum target of $20,000 and a maximum target of $5 million. The campaign proceeds will be used to fund pre-clinical animal trials and IND filings for a new intravenous drug delivery system.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$879,786

$891,911

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$212,834

$198,240

Accounts Receivable

$0

$0

Total Assets

$212,834

$198,240

Short-Term Debt

$0

$0

Long-Term Debt

$120,000

$0

Total Liabilities

$120,000

$0

Financials as of: 10/04/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Isosceles Pharmaceuticals on Equifund CFP 2022
Platform: Equifund CFP
Security Type: Equity - Common
Valuation: $30,800,000
Price per Share: $2.05

Follow company

Follow Isosceles Pharmaceuticals on Equifund CFP 2022

Buy Isosceles Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Isosceles Pharmaceuticals may no longer be accepting investments.

Isosceles Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on Isosceles Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Isosceles Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Isosceles Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge